Marina S. Penney

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

Timothy A. Yap, Brent O’Carrigan, Marina S. Penney et al. · Journal of Clinical Oncology · 2020 · 248 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

Luc J. Farmer, Mark W. Ledeboer, Thomas Hoock et al. · Journal of Medicinal Chemistry · 2015 · 89 citations

Medicine, Medicinal Chemistry, Pharmacology +13

Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.

Brent O’Carrigan, Maria J. de Miguel, D. Papadatos-Pastos et al. · Journal of Clinical Oncology · 2016 · 34 citations

Medicine, Oncology, Pharmacology +14

Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792).

Elizabeth Ruth Plummer, Emma Dean, T.R. Jeffry Evans et al. · Journal of Clinical Oncology · 2016 · 31 citations

Medicine, Oncology, Pharmacology +14

Telaprevir‐based treatment effects on hepatitis C virus in liver and blood

Andrew H. Talal, Rositsa B. Dimova, Eileen Z. Zhang et al. · Hepatology · 2014 · 21 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17